F&S reviews最新文献

{"title":"Fertility considerations in individuals affected by human immunodeficiency virus: a scoping review","authors":"Anisha R. Chada M.D. , Kerri E. Andre M.D. , Noor Al-Shibli M.D. , Heather S. Hipp M.D.","doi":"10.1016/j.xfnr.2025.100095","DOIUrl":"10.1016/j.xfnr.2025.100095","url":null,"abstract":"<div><h3>Objective</h3><div>Human immunodeficiency virus (HIV) has transformed from an almost universally terminal diagnosis to that of a chronic manageable condition over the last 4 decades. Patients of reproductive age make up the largest proportion of those with HIV. Our aim in this scoping review was to investigate how HIV sequelae, comorbidities, and antiretroviral treatment affect both male fertility and female fertility.</div></div><div><h3>Evidence Review</h3><div>A scoping review identified relevant articles on HIV, fertility, assisted reproductive technology, and HIV treatment. Included articles had one of the following study designs: prospective; retrospective; controlled; randomized controlled; or observational. Articles were excluded if they were of inappropriate study design or published in a non-English language. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines were used to assess eligibility of studies identified through PubMed, and manuscripts were reviewed independently by 2 reviewers.</div></div><div><h3>Results</h3><div>Fifty-nine manuscripts were included in the final qualitative synthesis, including 9 prospective studies, 14 retrospective studies, 35 observational studies, and 1 clinical trial. Articles on male fertility (n = 10) mainly focused on effects of HIV and/or antiretrovirals on semen quality, finding some level of abnormality in semen parameters compared with controls. Small observational studies (n = 4) found statistically significant effects of antiretroviral therapy on semen parameters. Large observational studies (n = 2) examining outcomes for serodiscordant couples pursuing intrauterine insemination with HIV+ male partner showed pregnancy outcomes comparable to those of controls. In studies examining outcomes of in vitro fertilization for serodiscordant couples with HIV+ male partner (n = 5), pregnancy outcomes were comparable to those of controls. In female patients with HIV (n = 7), HIV infection was associated with ovarian dysfunction and/or oligomenorrhea or prolonged amenorrhea. Markers of severe disease, such as a low CD4 count or viremia, were shown to be correlated with lower antimüllerian hormone levels. Three studies illustrated how the effects of comorbidities such as history of smoking, drug use, or pelvic infections can also compound infertility in these patients. Several cohort studies (n = 13) showed increased time to pregnancy, decreased pregnancy rates with and without in vitro fertilization, and an increased risk of spontaneous abortion. Given that the current backbone of preconception and antepartum management of HIV includes dual therapy with nucleoside reverse transcriptase inhibitors (NRTIs), most of the studies (n = 7) focused on NRTI’s potential toxicities such as mitochondrial depletion in gametes. In vitro and animal studies (n = 3) have shown negative implications on oocyte fertilizability and genomic disturbances in offs","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 2","pages":"Article 100095"},"PeriodicalIF":0.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144614276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertility care in transgender and gender-diverse individuals: the possibility of oocyte and sperm cryopreservation after medical transition","authors":"Kyle Le M.D. ,&nbsp;Atoosa Ghofranian M.D. ,&nbsp;Kate Devine M.D.","doi":"10.1016/j.xfnr.2025.100093","DOIUrl":"10.1016/j.xfnr.2025.100093","url":null,"abstract":"<div><div>Some transgender and gender-diverse individuals desire biological children; however, only a small percentage of these individuals preserve their fertility. There are many barriers preventing such patients from accessing assisted reproductive technologies. Many of them are not informed regarding fertility preservation options before initiation of gender-affirming hormonal therapy (GAHT). Transgender women and transfeminine individuals have worse semen parameters than cisgender men, even without exposure to GAHT. For those who seek GAHT, estradiol and/or antiandrogens may negatively impact semen parameters. Although a hiatus from GAHT before sperm cryopreservation may be considered, this may impose hardship. Transgender men and transmasculine individuals on GAHT have similar oocyte retrieval outcomes compared with transgender men not on GAHT and cisgender women. Multiple reports have indicated positive outcomes even in those who continue their testosterone through the oocyte stimulation cycle. Ideally, transgender and gender-diverse individuals should see a reproductive endocrinologist for a discussion of fertility preservation options and, if desired, should ideally complete fertility preservation <em>before</em> starting GAHT. Still, for several reasons, patients may decline or omit this step before initiating medical transition and then decide later that they wish to pursue fertility preservation or treatment. Thankfully for transgender males, data indicates that successful fertility preservation is possible even after medical transition. For transgender females, estradiol may reduce fertility potential, and outcomes after medical transition can be more limited.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 2","pages":"Article 100093"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144517776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blastocyst development in assisted reproductive technologies: a narrative review evaluating its role as a surrogate marker for pregnancy outcomes and live birth success","authors":"Dean E. Morbeck Ph.D. ,&nbsp;Michael P. Diamond M.D.","doi":"10.1016/j.xfnr.2025.100094","DOIUrl":"10.1016/j.xfnr.2025.100094","url":null,"abstract":"<div><div>There is an urgent global need to improve in vitro fertilization success rates and expand access to services. Specific to the in vitro fertilization laboratory, challenges such as standardization and a shortage of trained embryologists hinder quality and limit service availability. Current standards for product approval rely on demonstrating comparable pregnancy rates, requiring extensive patient involvement and time-consuming trials, which may be further hindered by patient reluctance to participate in clinical trials. Efficient assessment of new protocols and devices for assessing human assisted reproductive technology requires considering intermediate endpoints and markers to complement conventional endpoints. This review explores blastocyst development as a potential surrogate marker for pregnancy. It examines the correlation between blastocyst development and implantation potential, evaluates how culture conditions and other factors affect outcomes, and discusses the evidence supporting an absence of adverse effects of embryo culture on perinatal and offspring health. The conclusion strongly suggests that blastocyst development could serve as a valuable surrogate for establishing equivalency of pregnancy and live births in new assisted reproductive technology protocols. This review underscores the need for a surrogate marker of quality and presents evidence supporting the utility of blastocyst use rate as a sufficient indicator.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 2","pages":"Article 100094"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144513645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction notice to ‘The impact of an endometrial receptivity array on personalizing embryo transfer for patients with infertility: a meta-analysis’ (F S Rev 2022;3:157-73)","authors":"","doi":"10.1016/j.xfnr.2024.100080","DOIUrl":"10.1016/j.xfnr.2024.100080","url":null,"abstract":"","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100080"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunocompetent mouse models of endometriosis: a systematic review and meta-analysis","authors":"John Coté M.D. ,&nbsp;Remington Coté C.P.T. ,&nbsp;Isabella Zent B.S. ,&nbsp;Kate Woods B.S. ,&nbsp;Katherine Kedeshian B.S. ,&nbsp;Mya Hendry B.S. ,&nbsp;Kaylee Dykstal M.D. ,&nbsp;Ryan W. Walters Ph.D.","doi":"10.1016/j.xfnr.2025.100091","DOIUrl":"10.1016/j.xfnr.2025.100091","url":null,"abstract":"<div><h3>Objective</h3><div>To synthesize and compare measurable parameters researchers have used in the different immunocompetent mouse models of endometriosis.</div></div><div><h3>Evidence Review</h3><div>A systematic literature search of English language studies within PubMed/MEDLINE, Scopus, and Google Scholar from inception until January 2024 was performed. We included studies that reported an immunocompetent mouse model of intra-abdominal endometriosis and recorded at least one quantifiable lesion measurement with associated SDs or standard errors.</div></div><div><h3>Results</h3><div>The systematic search retrieved 1,421 studies, of which 236 underwent a full text review. A total of 163 studies met inclusion criteria for the meta-analysis. Within the suture (n = 76 studies) and injection (n = 88 studies) models there were multiple outcomes evaluated. The overall effect for lesion weight (33.1 mg, 95% confidence interval [CI], 23.8–45.9), lesion volume (15.6 mm³, 95% CI, 12.2–19.9), lesion area (8.6 mm², 95% CI, 5.6–13.4), lesion diameter (3.8 mm, 95% CI, 2.8–5.2), and lesion number (3.33, 95% CI, 2.8–3.8). Significant heterogeneity was observed for all outcomes. Meta-regression showed BALB/c strain, days of disease, and receiving estrogen affected lesion weight, injection, days of disease, and autologous donor/recipient affected lesion volume, days of disease affected lesion area, days of disease, and myometrium plus endometrium affected lesion diameter and BALB/c, receiving estrogen, and autologous donor/recipient affected lesion number.</div></div><div><h3>Conclusion</h3><div>The degree of heterogeneity, risk of bias, and low quality of evidence emphasize the need for a call to action. Model standardization, agreed on by the clinical and translational research community, would improve reproducibility and allow for evidenced-based translational outcomes, especially in the setting of preclinical endometriosis studies.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 2","pages":"Article 100091"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144138207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo gamete toxicology in the context of in vitro fertilization: a narrative review","authors":"Morgan Orsolini M.S. ,&nbsp;Jason Russack M.S. ,&nbsp;Huey Huynh M.S. ,&nbsp;Douglas Raburn Ph.D. ,&nbsp;John Fox Ph.D. ,&nbsp;Danny Schust M.D.","doi":"10.1016/j.xfnr.2025.100090","DOIUrl":"10.1016/j.xfnr.2025.100090","url":null,"abstract":"<div><div>In vitro fertilization (IVF) as a clinical method to surmount infertility has existed since the 1970s, and yet fertilization, embryo development, pregnancy, and live birth rates remain unacceptably low. Although a multitude of factors may contribute to stagnated success despite substantial advances in basic and applied IVF sciences, gamete quality is inarguably integral to IVF treatment success rates. In this review, the investigators explored the role of environmental toxicology in impairing in vivo fertility and gamete quality before starting IVF, which may influence downstream IVF treatment success. In vivo, contaminants of interest that may affect gamete potential in the context of IVF treatment include heavy metals, perfluoroalkyl and polyfluoroalkyl substances, persistent organic pollutants, and airborne contaminants. This review aimed to provide clinicians with a comprehensive reference on potential toxicologic exposures by evaluating the existing literature on reproductive toxicology and the impact of toxic exposures on IVF clinical outcomes. It used in vitro and animal data to support correlational human studies with potential causative mechanisms and to emphasize the importance of patient evaluation of toxicologic risk.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100090"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelial-mesenchymal transition links inflammation and fibrosis in the pathogenesis of endometriosis: a narrative review","authors":"Zoé I. Vincent-Mistiaen Ph.D.","doi":"10.1016/j.xfnr.2025.100089","DOIUrl":"10.1016/j.xfnr.2025.100089","url":null,"abstract":"<div><div>Endometriosis, a chronic inflammatory condition, is characterized by the growth of endometrial-like tissue outside the uterus, leading to debilitating pain and infertility. Although retrograde menstruation is widely accepted as a mechanism for the dissemination of endometrial cells to ectopic sites, the processes that enable their survival, invasion, and lesion formation remain incompletely understood. Epithelial-mesenchymal transition (EMT) has emerged as a potential driver, promoting cellular plasticity that supports ectopic implantation and invasion. Epithelial-mesenchymal transition is closely linked to inflammation, with transforming growth factor-β–mediated pathways playing a central role in driving these transitions. Chronic inflammation also induces fibroblast-myofibroblast transition (FMT) and smooth muscle metaplasia, processes that exacerbate fibrosis through excessive extracellular matrix deposition and fibroblast activation. These fibrotic changes worsen symptoms and contribute to disease progression. This review explores EMT and FMT as key mechanistic links between inflammation and fibrosis and discusses how targeting these pathways could offer novel therapeutic strategies to disrupt fibrotic progression, alleviate symptoms, and improve patient outcomes. Additionally, EMT and FMT markers hold promise as diagnostic tools, offering potential for earlier detection and more precise staging of endometriosis.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100089"},"PeriodicalIF":0.0,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of clinical touch, 2D, 3D, and 4D ultrasound guided embryo transfer: a systematic review and network meta-analysis of embryo transfer techniques","authors":"Yusuf Beebeejaun M.R.C.O.G. ,&nbsp;Timothy Copeland Ph.D. ,&nbsp;Ippokratis Sarris D.M., F.R.C.O.G. ,&nbsp;Marian Showell M.P.H. ,&nbsp;Sesh K. Sunkara M.R.C.O.G. ,&nbsp;James M.N. Duffy D.Phil.","doi":"10.1016/j.xfnr.2025.100088","DOIUrl":"10.1016/j.xfnr.2025.100088","url":null,"abstract":"<div><h3>Objective</h3><div>With the use of two-dimensional ultrasound (2D US) in embryo transfer (ET) procedures now a widely accepted practice, and preferred over clinical touch (CT), there is growing interest in whether three-dimensional (3D) and four-dimensional (4D) US provide better outcomes for ET compared with traditional 2D methods. We aim to perform a network meta-analysis (NMA) to compare the clinical efficacy and safety of CT, 2D transabdominal (TAUS), 2D transvaginal (TVUS), 3D, and 4D US-guided ET.</div></div><div><h3>Evidence Review</h3><div>Randomized controlled trials (RCTs) indexed in PubMed, MEDLINE, EMBASE, clinical trial registries, and Cochrane Database of Systematic Reviews were searched from inception to December 2023. Identified RCTs were assessed for trustworthiness using the Trustworthiness in RAndomized Controlled Trials. Statistical analysis for pairwise was performed using Review Manager version 5.3 and NMAs were performed using STATA version 16. Random-effects modeling was used for data-pooling. Key outcomes included clinical pregnancy (CPRs) and live birth rates (LBRs), miscarriage rates, and ectopic pregnancy rates.</div></div><div><h3>Results</h3><div>Twenty-five RCTs of high integrity assessing 8,884 ET outcomes comparing CT, 2D TAUS-, 2D TVUS-, 3D TAUS-, and 4D TVUS-guided ET were included. The NMA identified lower LBR with CT (risk ratio [RR]: 0.78, 95% confidence interval [CI]: 0.59–1.03) compared with 2D TAUS. There were no significant differences in LBR between other methods, including 2D TVUS vs. 2D TAUS (RR: 1.03, 95% CI: 0.61–1.74), and 3D TAUS vs. 2D TAUS (RR: 1.01, 95% CI: 0.78–1.32). Clinical touch-guided ET was associated with a lower CPR compared with 2D TAUS (RR: 0.83, 95% CI: 0.75–0.91). There was no significant CPR difference comparing 2D TVUS vs. 2D (RR: 0.98, 95% CI: 0.83–1.16), 3D TAUS vs. 2D TAUS (RR 0.98, 95% CI: 0.80–1.20). Four-dimensional TVUS did not show a significant difference in either LBR or CPR compared with 2D TAUS, 3D TAUS, or CT.</div></div><div><h3>Conclusion</h3><div>For CPR, our study reinforces that ET guided by CT alone is inferior to 2D TAUS-guided transfer. However, when comparing 2D TAUS-, 2D TVUS-, 3D TAUS-, and 4D TVUS-guided ET, we found no evidence of significant differences in LBR, CPR, miscarriage rates, or ectopic pregnancy rates. The certainty of evidence for our primary outcome of CPR was rated as moderate, reflecting confidence in the results, but with notable concerns regarding study limitations and paucity of trials assessing the use of 3D and 4D US.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100088"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143644957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fertoprotective agents and tumor response: a narrative review","authors":"Addison W. Alley M.D. ,&nbsp;Jonathan E. Constance Ph.D. ,&nbsp;Joseph M. Letourneau M.D.","doi":"10.1016/j.xfnr.2025.100087","DOIUrl":"10.1016/j.xfnr.2025.100087","url":null,"abstract":"<div><div>As advances in cancer therapy have significantly improved mortality rates, there is increasing emphasis on improving quality of life for cancer survivors. One such area of focus is in maintaining fertility, as both chemotherapy and radiation therapy carry significant risks of causing infertility through various mechanisms of gonadal injury. Although fertility preservation options exist, such as sperm or egg banking, they are not always available or indicated for all patients. Fertoprotective agents are proposed substances that may serve to protect the gonad from the harmful impacts of cancer therapy to maintain fertility. However, caution must be taken to evaluate whether these agents could act similarly to protect the tumor from anticancer therapies. In this narrative review, we first describe the various mechanisms by which chemotherapy or radiation therapy can cause gonadal harm. We then review the available research on fertoprotective agents and their proposed mechanisms of gonadal protection. Finally, we discuss what evidence exists for interaction with cancer therapy for each agent, with an emphasis on opportunities for future research.</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100087"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the risk of ovarian hyperstimulation syndrome in women undergoing assisted reproductive technology treatments: a systematic review and quality assessment of prediction models","authors":"Krishnika Vetrivel M.B.B.S. ,&nbsp;Ayesha Salejee M.B.B.S. ,&nbsp;Bheena Kharunyam M.B.B.S. ,&nbsp;Hakim-Moulay Dehbi Ph.D. ,&nbsp;Spiros Denaxas Ph.D. ,&nbsp;Nicholas Freemantle Ph.D. ,&nbsp;Bassel H. Al Wattar Ph.D.","doi":"10.1016/j.xfnr.2024.100086","DOIUrl":"10.1016/j.xfnr.2024.100086","url":null,"abstract":"<div><h3>Importance</h3><div>Ovarian hyperstimulation syndrome (OHSS) is a common iatrogenic complication of controlled ovarian stimulation (COS) in assisted conception. OHSS can be life-threatening and associated with significant morbidity. Several measures could help prevent OHSS; however, accurate risk prediction remains a challenge to enable early prevention.</div></div><div><h3>Objective</h3><div>To review available prediction models for OHSS in women undergoing assisted conception and to identify the best-performing models for their accuracy, generalizability, and applicability.</div></div><div><h3>Evidence review</h3><div>We searched electronic databases (MEDLINE, EMBASE, and CENTRAL) until October 2023. We included studies reporting on the development or evaluation of models predicting the risk of OHSS outcomes before or during COS among women undergoing assisted conception. We reported on models’ discrimination, calibration, type of validation, and any implementation tools for clinical practice.</div></div><div><h3>Findings</h3><div>We screened 5,699 citations and included 14 observational cohort studies reporting on 14 prediction models. The median sample size was 782 participants (range 105–256,381), and the majority of models were developed using logistic regression (13/14, 92.9%). The commonest predictor was maternal age (7/14, 50.0%), followed by number of antral and mature follicles (6/14, 42.9%). Six models were internally validated (6/14, 42.9%), and none were externally validated. Only one model had an implementation platform as a smartphone-based application (1/14, 7.1%). Most of the included studies had an unclear risk of bias (7/14, 50.0%), and only three studies were at low risk (3/13, 21.4%).</div></div><div><h3>Conclusion and relevance</h3><div>There are no clinically appropriate and validated prediction models for OHSS among women undergoing controlled ovarian stimulation. More research is needed to improve their generalizability and applicability into clinical practice.</div></div><div><h3>PROSPERO</h3><div>CRD42024509423</div></div>","PeriodicalId":73011,"journal":{"name":"F&S reviews","volume":"6 1","pages":"Article 100086"},"PeriodicalIF":0.0,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}